L. , Ulcerative colitis-Disease Activity Index) ou « score Mayo

, Il s'agit du score le plus utilisé à ce jour. La RCH est dite active quand le score est entre 6 et 12

L. Uceis,

, L'item « friabilité » a disparu car non reproductible. Ce score a été récemment validé

J. Rambaud, Traité de Gastroentérologie. Flammarion, 2005.

N. A. Molodecky, I. S. Soon, D. M. Rabi, W. A. Ghali, M. Ferris et al., Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review, Gastroenterology, vol.142, issue.1, pp.46-54, 2012.

C. Gower-rousseau, F. Vasseur, M. Fumery, G. Savoye, J. Salleron et al., Epidemiology of inflammatory bowel diseases: New insights from a French population-based registry (EPIMAD). Dig Liver Dis, vol.45, pp.89-94, 2013.
DOI : 10.1016/j.dld.2012.09.005

URL : https://hal.archives-ouvertes.fr/hal-01701899

S. Shivananda, J. Lennard-jones, R. Logan, N. Fear, A. Price et al., Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD), Gut, vol.39, issue.5, pp.690-697, 1996.

Y. Zhang and Y. Li, Inflammatory bowel disease: pathogenesis, World J Gastroenterol, vol.20, issue.1, pp.91-100, 2014.

G. V. Assche, A. Dignass, J. Panes, L. Beaugerie, J. Karagiannis et al., The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis, J Crohns Colitis, vol.4, issue.1, pp.7-27, 2010.

F. Parente, S. Greco, M. Molteni, C. Cucino, G. Maconi et al., Role of early ultrasound in detecting inflammatory intestinal disorders and identifying their anatomical location within the bowel, Aliment Pharmacol Ther, vol.15, issue.10, pp.1009-1025, 2003.

J. Panes, Y. Bouhnik, W. Reinisch, J. Stoker, S. A. Taylor et al., Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines, J Crohns Colitis, vol.7, issue.7, pp.556-85, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01704202

A. Dignass, R. Eliakim, F. Magro, C. Maaser, Y. Chowers et al., Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis, J Crohns Colitis, vol.6, issue.10, pp.965-90, 2012.

G. K. Makharia, S. Srivastava, P. Das, P. Goswami, U. Singh et al., Clinical, endoscopic, and histological differentiations between Crohn's disease and intestinal tuberculosis, Am J Gastroenterol, vol.105, issue.3, pp.642-51, 2010.

A. Kandiel and B. Lashner, Cytomegalovirus colitis complicating inflammatory bowel disease, Am J Gastroenterol, vol.101, issue.12, pp.2857-65, 2006.

C. Canavan, K. R. Abrams, and J. Mayberry, Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease, Aliment Pharmacol Ther, vol.23, issue.8, pp.1097-104, 2006.

T. Jess, C. Rungoe, and L. Peyrin-biroulet, Risk of colorectal cancer in patients with ulcerative colitis: a metaanalysis of population-based cohort studies, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc, vol.10, issue.6, pp.639-684, 2012.

G. Assche, A. Dignass, B. Bokemeyer, S. Danese, P. Gionchetti et al.,

, Rev Gastroenterol México, vol.80, issue.1, pp.74-106, 2015.

M. Claessen, F. P. Vleggaar, K. Tytgat, P. D. Siersema, . Van-buuren et al., High lifetime risk of cancer in primary sclerosing cholangitis, J Hepatol, vol.50, issue.1, pp.158-64, 2009.

F. Magro, L. Peyrin-biroulet, H. Sokol, X. Aldeger, A. Costa et al., Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III), J Crohns Colitis, vol.8, issue.1, pp.31-44, 2014.
URL : https://hal.archives-ouvertes.fr/hal-00829286

L. Peyrin-biroulet, M. Ferrante, F. Magro, S. Campbell, D. Franchimont et al., Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease, J Crohns Colitis, vol.5, issue.5, pp.477-83, 2011.

L. Peyrin-biroulet, G. Bonnaud, A. Bourreille, J. Chevaux, P. Faure et al., Endoscopy in inflammatory bowel disease: recommendations from the IBD Committee of the French Society of Digestive Endoscopy (SFED), Endoscopy, vol.45, issue.11, pp.936-979, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01701888

M. Daperno, D. 'haens, G. Van-assche, G. Baert, F. Bulois et al., Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD, Gastrointest Endosc, vol.60, issue.4, pp.505-517, 2004.

P. Rutgeerts, K. Geboes, G. Vantrappen, J. Beyls, R. Kerremans et al., Predictability of the postoperative course of Crohn's disease, Gastroenterology, vol.99, issue.4, pp.956-63, 1990.

D. 'haens, G. Sandborn, W. J. Feagan, B. G. Geboes, K. Hanauer et al., A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis, Gastroenterology, vol.132, issue.2, pp.763-86, 2007.

S. Travis, D. Schnell, P. Krzeski, M. T. Abreu, D. G. Altman et al., Reliability and initial validation of the ulcerative colitis endoscopic index of severity, Gastroenterology, vol.145, issue.5, pp.987-95, 2013.

V. Subramanian, J. Mannath, K. Ragunath, and C. J. Hawkey, Meta-analysis: the diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease, Aliment Pharmacol Ther, vol.33, issue.3, pp.304-316, 2011.

E. K. Wright, Calprotectin or Lactoferrin: Do They Help, Dig Dis Basel Switz, vol.34, issue.1-2, pp.98-104, 2016.

D. Foell, H. Wittkowski, and J. Roth, Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage, Gut, vol.58, issue.6, pp.859-68, 2009.

U. Kopylov, G. Rosenfeld, B. Bressler, and E. Seidman, Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease, Inflamm Bowel Dis, vol.20, issue.4, pp.742-56, 2014.

Y. Wang, F. Pei, X. Wang, Z. Sun, C. Hu et al., Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis, Int J Clin Exp Pathol, vol.8, issue.10, pp.12319-12351, 2015.

M. K. Fagerhol, Calprotectin, a faecal marker of organic gastrointestinal abnormality, Lancet Lond Engl, vol.356, issue.9244, pp.1783-1787, 2000.

J. P. Gisbert and A. G. Mcnicholl, Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease, Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver, vol.41, issue.1, pp.56-66, 2009.

C. Otten, L. Kok, B. Witteman, R. Baumgarten, E. Kampman et al., Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome, Clin Chem Lab Med, vol.46, issue.9, pp.1275-80, 2008.

P. F. Van-rheenen, E. Van-de-vijver, and V. Fidler, Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis, BMJ, vol.341, p.3369, 2010.

Z. Yang, N. Clark, and K. T. Park, Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc, vol.12, issue.2, pp.253-62, 2014.

C. Cellier, T. Sahmoud, E. Froguel, A. Adenis, J. Belaiche et al., Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des, Affections Inflammatoires Digestives. Gut, vol.35, issue.2, pp.231-236, 1994.
DOI : 10.1136/gut.35.2.231

URL : https://gut.bmj.com/content/35/2/231.full.pdf

J. M. Benítez and V. García-sánchez, Faecal calprotectin: Management in inflammatory bowel disease, World J Gastrointest Pathophysiol, vol.6, issue.4, pp.203-212, 2015.

D. 'haens, G. Ferrante, M. Vermeire, S. Baert, F. Noman et al., Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease, Inflamm Bowel Dis, vol.18, issue.12, pp.2218-2242, 2012.

T. Lobatón, A. López-garcía, F. Rodríguez-moranta, A. Ruiz, L. Rodríguez et al., A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease, J Crohns Colitis, vol.7, issue.12, pp.641-51, 2013.

R. Mao, Y. Xiao, X. Gao, B. Chen, Y. He et al., Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies, Inflamm Bowel Dis, vol.18, issue.10, pp.1894-1903, 2012.

T. Sipponen, E. Savilahti, P. Kärkkäinen, K. Kolho, H. Nuutinen et al., Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease, Inflamm Bowel Dis, vol.14, issue.10, pp.1392-1400, 2008.
DOI : 10.1002/ibd.20490

C. Af-björkesten, U. Nieminen, U. Turunen, P. Arkkila, T. Sipponen et al., Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease, Scand J Gastroenterol, vol.47, issue.5, pp.528-565, 2012.

C. A. Lamb, M. K. Mohiuddin, J. Gicquel, D. Neely, F. G. Bergin et al., Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease, Br J Surg, vol.96, issue.6, pp.663-74, 2009.
DOI : 10.1002/bjs.6593

G. Boschetti, . Laidet-m-'harid, D. Moussata, C. Stefanescu, X. Roblin et al., Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn's Disease, Am J Gastroenterol, vol.110, issue.6, pp.865-72, 2015.

G. T. Ho, H. M. Lee, G. Brydon, T. Ting, N. Hare et al., Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis, Am J Gastroenterol, vol.104, issue.3, pp.673-681, 2009.

B. Moum, J. Jahnsen, and T. Bernklev, Fecal calprotectin variability in Crohn's disease. Inflamm Bowel Dis, vol.16, pp.1091-1093, 2010.
DOI : 10.1002/ibd.21136

G. D. Naismith, L. A. Smith, S. Barry, J. I. Munro, S. Laird et al., A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease, Aliment Pharmacol Ther, vol.37, issue.6, pp.613-634, 2013.

W. Lim and S. Hanauer, Aminosalicylates for induction of remission or response in Crohn's disease, Cochrane Database Syst Rev, issue.12, p.8870, 2010.

B. G. Feagan and J. K. Macdonald, Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev, vol.10, p.544, 2012.

A. Dignass, J. O. Lindsay, A. Sturm, A. Windsor, J. Colombel et al., Second European evidencebased consensus on the diagnosis and management of ulcerative colitis part 2: current management, J Crohns Colitis, vol.6, issue.10, pp.991-1030, 2012.

N. Chande, P. H. Patton, D. J. Tsoulis, B. S. Thomas, and J. K. Macdonald, Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease, Cochrane Database Syst Rev, vol.10, p.67, 2015.

A. Timmer, J. Mcdonald, D. J. Tsoulis, and J. K. Macdonald, Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev, vol.9, p.478, 2012.

A. Kandiel, A. G. Fraser, B. I. Korelitz, C. Brensinger, and J. D. Lewis, Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine, Gut, vol.54, issue.8, pp.1121-1126, 2005.

V. Patel, J. K. Macdonald, J. W. Mcdonald, and N. Chande, Methotrexate for maintenance of remission in Crohn's disease, Cochrane Database Syst Rev, issue.4, p.6884, 2009.

Y. Wang, J. K. Macdonald, B. Vandermeer, A. M. Griffiths, and W. El-matary, Methotrexate for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev, vol.8, p.7560, 2015.

S. Lichtiger, D. H. Present, A. Kornbluth, I. Gelernt, J. Bauer et al., Cyclosporine in severe ulcerative colitis refractory to steroid therapy, N Engl J Med, vol.330, issue.26, pp.1841-1846, 1994.
DOI : 10.1056/nejm199406303302601

R. Panaccione, S. Ghosh, S. Middleton, J. R. Márquez, B. B. Scott et al., Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis, Gastroenterology, vol.146, issue.2, pp.392-400, 2014.
DOI : 10.1053/j.gastro.2013.10.052

D. 'haens, G. Baert, F. Van-assche, G. Caenepeel, P. Vergauwe et al., Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial, Lancet Lond Engl, vol.371, issue.9613, pp.660-667, 2008.

, Quand débuter un traitement anti-TNF ?

F. , , 2016.

, Chloé Maréchal 1,2 ; Isabelle Aimone-Gastin 4

, Laurent Peyrin-Biroulet, vol.1, issue.2

I. U954,

J. Abbvie, . Genentech, . Mitsubishi, . Ferring, . Norgine et al., Abbreviations used in this paper: IBD: Inflammatory Bowel Disease UC: Ulcerative colitis CD: Crohn disease FC: Fecal Calprotectin Disclosures: LPB: Consulting fees from Merck

D. C. Baumgart and W. J. Sandborn, Inflammatory bowel disease: clinical aspects and established and evolving therapies, Lancet, vol.369, pp.1641-57, 2007.

L. Peyrin-biroulet, M. Ferrante, F. Magro, S. Campbell, D. Franchimont et al., Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease, J Crohns Colitis, vol.5, pp.477-83, 2011.

F. Schnitzler, H. Fidder, M. Ferrante, M. Noman, I. Arijs et al., Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease, Inflamm Bowel Dis, pp.1295-301, 2009.

D. 'haens, G. Baert, F. Van-assche, G. Caenepeel, P. Vergauwe et al., Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial, Lancet Lond Engl, vol.371, pp.660-667, 2008.

P. Rutgeerts, G. Van-assche, W. J. Sandborn, D. C. Wolf, K. Geboes et al., Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial, Gastroenterology, vol.142, pp.1102-1113, 2012.

P. Rutgeerts, W. J. Sandborn, B. G. Feagan, W. Reinisch, A. Olson et al., Infliximab for induction and maintenance therapy for ulcerative colitis, N Engl J Med, vol.353, pp.2462-76, 2005.

L. Peyrin-biroulet, W. Sandborn, B. E. Sands, W. Reinisch, W. Bemelman et al., Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target, Am J Gastroenterol, vol.110, pp.1324-1362, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01191653

V. Annese, M. Daperno, M. D. Rutter, A. Amiot, P. Bossuyt et al., European evidence based consensus for endoscopy in inflammatory bowel disease, J Crohns Colitis, vol.7, pp.982-1018, 2013.

C. Dubé, Minor adverse events postcolonoscopy, Can J Gastroenterol Hepatol, vol.28, p.606, 2014.

T. H. Lüning, M. E. Keemers-gels, W. B. Barendregt, A. Tan, and C. Rosman, Colonoscopic perforations: a review of 30,366 patients, Surg Endosc, vol.21, pp.994-1001, 2007.

M. H. Svensson, E. Svensson, A. Lasson, and M. Hellström, Patient acceptance of CT colonography and conventional colonoscopy: prospective comparative study in patients with or suspected of having colorectal disease, Radiology, vol.222, pp.337-382, 2002.

M. H. Mosli, G. Zou, S. K. Garg, S. G. Feagan, J. K. Macdonald et al., C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis, Am J Gastroenterol, vol.110, pp.802-821, 2015.

J. Benitez, M. Meuwis, C. Reenaers, C. Van-kemseke, P. Meunier et al., Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring, Gut, vol.62, pp.1806-1822, 2013.

U. Kopylov, G. Rosenfeld, B. Bressler, and E. Seidman, Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease, Inflamm Bowel Dis, vol.20, pp.742-56, 2014.

J. Langhorst, S. Elsenbruch, J. Koelzer, A. Rueffer, A. Michalsen et al., Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices, Am J Gastroenterol, vol.103, pp.162-171, 2008.

J. P. Gisbert, F. Bermejo, J. Pérez-calle, C. Taxonera, I. Vera et al., Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse, Inflamm Bowel Dis, vol.15, pp.1190-1198, 2009.

A. G. Røseth, M. K. Fagerhol, E. Aadland, and H. Schjønsby, Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study, Scand J Gastroenterol, vol.27, pp.793-801, 1992.

S. H. Saverymuttu, A. M. Peters, M. E. Crofton, H. Rees, J. P. Lavender et al., 111Indium autologous granulocytes in the detection of inflammatory bowel disease, Gut, vol.26, pp.955-60, 1985.

J. Lin, J. Chen, J. Zuo, Y. A. Xiao, Z. Deng et al., Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity, Inflamm Bowel Dis, vol.20, pp.1407-1422, 2014.

R. Mao, Y. Xiao, X. Gao, B. Chen, Y. He et al., Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies, Inflamm Bowel Dis, vol.18, pp.1894-1903, 2012.

D. 'haens, G. Ferrante, M. Vermeire, S. Baert, F. Noman et al., Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease, Inflamm Bowel Dis, vol.18, pp.2218-2242, 2012.

M. De-vos, E. J. Louis, J. Jahnsen, J. Vandervoort, M. Noman et al., Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy, Inflamm Bowel Dis, vol.19, pp.2111-2118, 2013.

G. D. Naismith, L. A. Smith, S. Barry, J. I. Munro, S. Laird et al., A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease, Aliment Pharmacol Ther, vol.37, pp.613-634, 2013.

B. Moum, J. Jahnsen, and T. Bernklev, Fecal calprotectin variability in Crohn's disease, Inflamm Bowel Dis, vol.16, pp.1091-1093, 2010.

E. K. Wright, M. A. Kamm, D. Cruz, P. Hamilton, A. L. Ritchie et al., Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery, Gastroenterology, vol.148, pp.938-985, 2015.

G. Boschetti, . Laidet-m-'harid, D. Moussata, C. Stefanescu, X. Roblin et al., Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn's Disease, Am J Gastroenterol, vol.110, pp.865-72, 2015.

R. Ferreiro-iglesias, M. Barreiro-de-acosta, O. Santiago, M. , L. Gonzalez et al., Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy, J Clin Gastroenterol, 2015.

F. A. Macrae, S. John, D. J. Ambikapathy, A. Sharpe, K. Garner et al., Factors affecting compliance in colorectal cancer screening. Results of a study performed in Ballarat, Med J Aust, vol.144, pp.621-624, 1986.

D. Mant, A. Fuller, J. Northover, P. Astrop, A. Chivers et al., Patient compliance with colorectal cancer screening in general practice, Br J Gen Pract J R Coll Gen Pract, vol.42, pp.18-20, 1992.

A. Lopez, V. Billioud, C. Peyrin-biroulet, P. , and L. , Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review, Inflamm Bowel Dis, vol.19, pp.1528-1561

E. Vangeli, S. Bakhshi, A. Baker, A. Fisher, D. Bucknor et al., A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory Diseases, Adv Ther, vol.32, pp.983-1028, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01667551

T. J. Bramley, P. P. Gerbino, B. S. Nightengale, and F. Frech-tamas, Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations, J Manag Care Pharm JMCP, vol.12, pp.239-284, 2006.

C. Giorda, R. Picariello, N. E. Tartaglino, B. Marafetti, L. Costa et al., The impact of adherence to screening guidelines and of diabetes clinics referral on morbidity and mortality in diabetes, PloS One, vol.7, p.33839, 2012.

P. V. Burkhart and E. Sabaté, Adherence to long-term therapies: evidence for action, J Nurs Scholarsh Off Publ Sigma Theta Tau Int Honor Soc Nurs Sigma Theta Tau, vol.35, p.207, 2003.

C. A. Jackson, J. Clatworthy, A. Robinson, and R. Horne, Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review, Am J Gastroenterol, vol.105, pp.525-564, 2010.

A. Armuzzi, P. Gionchetti, M. Daperno, S. Danese, A. Orlando et al., Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-tosevere Inflammatory Bowel Disease. Dig Liver Dis, 2016.

L. Coorevits, F. J. Baert, and H. Vanpoucke, Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method, Clin Chem Lab Med, vol.5, pp.825-856, 2013.

G. Ogedegbe and A. Schoenthaler, A systematic review of the effects of home blood pressure monitoring on medication adherence, J Clin Hypertens Greenwich Conn, vol.8, pp.174-80, 2006.

F. Depont, F. Berenbaum, J. Filippi, L. Maitre, M. Nataf et al., Interventions to Improve Adherence in Patients with Immune-Mediated Inflammatory Disorders: A Systematic Review, PloS One, vol.10, p.145076, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01257916

J. Viguier, A. Calazel-benque, F. Eisinger, and X. Pivot, Organized colorectal cancer screening programmes: how to optimize efficiency among general practitioners, Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP, vol.20, issue.1, pp.26-32, 2011.